Advanced Pharmacology Course

Lesson 1 • Agonism, Antagonism, and Receptor Theory

Defines full, partial, and inverse agonists alongside competitive and non-competitive antagonists. Builds receptor occupancy theory as a predictive clinical tool.

Lesson 2 • Dose-Response Relationships

Analyses graded and quantal dose-response curves, potency, and efficacy. Establishes quantitative thinking required for therapeutic decision-making.

Lesson 3 • Signal Transduction Pathways

Maps G-protein, kinase, and nuclear receptor signalling cascades activated by drugs. Connects intracellular signalling to downstream therapeutic and adverse effects.

Lesson 4 • Cellular Targets of Drug Action

Examines receptors, enzymes, ion channels, and transporters as primary drug targets. Links molecular biology to observable pharmacological effects.

Lesson 1 • Renal and Extra-Hepatic Elimination

Covers glomerular filtration, tubular secretion, reabsorption, and non-renal clearance routes. Links renal function to dose adjustment requirements.

Lesson 2 • Compartmental Models and Half-Life

Applies one- and two-compartment models to describe drug concentration-time profiles. Enables calculation of half-life, steady state, and accumulation ratios.

Lesson 3 • Hepatic Drug Metabolism

Details Phase I and Phase II biotransformation reactions and cytochrome P450 enzymes. Predicts metabolic drug interactions and prodrug activation.

Lesson 4 • Drug Distribution and Volume of Distribution

Analyses plasma protein binding, tissue partitioning, and the volume of distribution concept. Explains why drug concentration in plasma may not reflect tissue levels.

Lesson 1 • Neuromuscular Junction Pharmacology

Covers depolarising and non-depolarising neuromuscular blockers and reversal agents. Directly applicable to anaesthesia practice and critical care management.

Lesson 2 • Autonomic Nervous System Architecture

Reviews sympathetic and parasympathetic anatomy, neurotransmitter synthesis, and receptor subtypes. Provides the physiological baseline for interpreting autonomic drug effects.

Lesson 3 • Adrenergic Antagonists in Clinical Practice

Analyses alpha-blockers and beta-blockers by selectivity, intrinsic activity, and therapeutic role. Addresses hypertension, heart failure, and phaeochromocytoma management.

Lesson 4 • Cholinergic Agonists and Antagonists

Examines direct and indirect cholinomimetics alongside muscarinic and nicotinic blockers. Connects mechanism to clinical uses in glaucoma, myasthenia, and anaesthesia.

Lesson 1 • Antihypertensive Drug Classes

Compares ACE inhibitors, ARBs, calcium channel blockers, diuretics, and direct vasodilators. Links mechanism to haemodynamic outcomes and patient-specific selection.

Lesson 2 • Antithrombotic and Thrombolytic Agents

Covers antiplatelet drugs, anticoagulants, and fibrinolytics across the coagulation cascade. Balances thrombotic risk against bleeding complications in clinical scenarios.

Lesson 3 • Antianginal and Antiischemic Drugs

Analyses nitrates, beta-blockers, and calcium channel blockers in reducing myocardial oxygen demand. Addresses stable angina, vasospasm, and acute coronary syndrome contexts.

Lesson 4 • Antiarrhythmic Agents

Applies the Vaughan Williams classification to sodium, potassium, and calcium channel blockers. Predicts proarrhythmic risk and selects agents by arrhythmia mechanism.

Lesson 1 • Neurotransmitter Systems as Drug Targets

Maps dopaminergic, serotonergic, GABAergic, and glutamatergic systems to CNS drug classes. Establishes the neurochemical basis for understanding psychotropic drug actions.

Lesson 2 • Anxiolytic and Sedative-Hypnotic Drugs

Examines benzodiazepines, Z-drugs, buspirone, and barbiturates by GABA receptor modulation. Addresses tolerance, dependence, and withdrawal management strategies.

Lesson 3 • Analgesics and Pain Pharmacology

Covers opioid receptor pharmacology, NSAIDs, and adjuvant analgesics across pain types. Integrates multimodal analgesia principles and opioid risk mitigation strategies.

Lesson 4 • Antidepressant Pharmacology

Analyses SSRIs, SNRIs, TCAs, and MAOIs by mechanism, onset, and interaction risk. Addresses serotonin syndrome, discontinuation syndrome, and augmentation strategies.

Lesson 5 • Antiepileptic Drug Pharmacology

Classifies antiepileptic drugs by mechanism and seizure type specificity. Addresses therapeutic drug monitoring, teratogenicity, and drug interaction profiles.

Lesson 1 • Immunosuppressant and Immunomodulatory Drugs

Analyses calcineurin inhibitors, mTOR inhibitors, biologics, and corticosteroids in immune modulation. Applies to transplant rejection, autoimmune disease, and inflammatory conditions.

Lesson 2 • Antiviral Pharmacology

Examines nucleoside analogs, protease inhibitors, and integrase inhibitors targeting viral replication. Covers HIV, influenza, herpesvirus, and hepatitis treatment frameworks.

Lesson 3 • Antifungal and Antiparasitic Agents

Covers azoles, polyenes, echinocandins, and antiparasitic drug classes by mechanism and toxicity. Addresses fungal resistance and drug selection in immunocompromised patients.

Lesson 4 • Antibacterial Drug Mechanisms

Categorises antibiotics by target: cell wall, protein synthesis, DNA replication, and membrane integrity. Links mechanism to spectrum of activity and bactericidal vs. bacteriostatic classification.

Lesson 1 • Bone and Calcium Homeostasis Drugs

Covers bisphosphonates, denosumab, teriparatide, and vitamin D analogs in bone metabolism. Applies to osteoporosis, hypercalcaemia, and Paget's disease management.

Lesson 2 • Lipid-Lowering Pharmacotherapy

Analyses statins, fibrates, PCSK9 inhibitors, and bile acid sequestrants by lipid-modifying mechanism. Links LDL reduction to cardiovascular risk reduction evidence.

Lesson 3 • Thyroid and Adrenal Pharmacology

Covers thyroid hormone synthesis inhibitors, replacement therapy, and adrenocortical agents. Addresses hyperthyroidism, hypothyroidism, Cushing's syndrome, and adrenal insufficiency.

Lesson 4 • Reproductive Endocrine Pharmacology

Examines oestrogens, progestins, androgens, and fertility agents by receptor mechanism and clinical use. Covers contraception, hormone replacement, and reproductive disorder management.

Lesson 1 • Monoclonal Antibody Therapeutics

Analyses naked antibodies, antibody-drug conjugates, and bispecific antibodies by mechanism of tumour killing. Covers HER2, VEGF, CD20, and PD-1/PD-L1 targeting strategies.

Lesson 2 • Immune Checkpoint Inhibitor Pharmacology

Examines PD-1, PD-L1, and CTLA-4 inhibitors restoring antitumour T-cell immunity. Addresses immune-related adverse events and biomarker-driven patient selection.

Lesson 3 • Cytotoxic Chemotherapy Mechanisms

Classifies alkylating agents, antimetabolites, topoisomerase inhibitors, and mitotic spindle poisons. Links cell cycle specificity to scheduling and combination rationale.

Lesson 4 • Chemotherapy Toxicity and Supportive Care

Covers myelosuppression, cardiotoxicity, nephrotoxicity, and neurotoxicity management strategies. Integrates antiemetic, growth factor, and cytoprotective pharmacology.